TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38720251

Group type: EXPERIMENTAL
Intervention: VR-based cognitive training (warm-up module and three tasks including one-back and dual-N-back)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (regular VR headset app showing nature videos)
Number of subjects: 72
Study: 38720312

Group type: EXPERIMENTAL
Intervention: Assisted index case testing (ICT)
Number of subjects: 26
Study: 38720363

Group type: COMPARATOR
Intervention: SBIRT (Screening, Brief Intervention and Referral to Treatment) delivered by trained lay health workers, followed by referral to treatment with varenicline prescribed and monitored by trained nurse prescribers.
Number of subjects: 750

Group type: COMPARATOR
Intervention: Enhanced standard of care (control group).
Number of subjects: 750
Study: 38720383

Group type: EXPERIMENTAL
Intervention: High dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive corticosteroids (prednisone 1.5 mg/kg/day) for the first 14 days of TB treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tuberculosis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety and tolerability endpoints
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 0
Study: 38720661

Group type: EXPERIMENTAL
Intervention: Cafedrine/theodrenaline (C/T) combination (20:1)
Number of subjects: 315
Study: 38720697

Group type: EXPERIMENTAL
Intervention: Spring group (n=178)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Summer group (n=155)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Autumn group (n=182)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Winter group (n=180)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Overall comparison of MACE across all groups
Number of subjects: 695
Study: 38720913

Group type: EXPERIMENTAL
Intervention: 4-week low-frequency rTMS targeting the right dorsolateral prefrontal cortex (rDLPFC) + treatment as usual (TAU) (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation + treatment as usual (TAU) (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only (for low FCR group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Post-treatment fMRI scan
Number of subjects: 50
Study: 38721015

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by liver transplantation (LT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Chemotherapy alone (C)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT)
Number of subjects: 157
Study: 38721358

Group type: EXPERIMENTAL
Intervention: Selumetinib 25 mg/m administered with a low-fat meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Selumetinib 25 mg/m administered in a fasted state
Number of subjects: 24
Study: 38721402

Group type: EXPERIMENTAL
Intervention: Lacnotuzumab (MCS110) in combination with Spartalizumab (PDR001)
Number of subjects: 8
Study: 38721639

Group type: EXPERIMENTAL
Intervention: Diabetes Body Project (DBP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 280
Study: 38721650

Group type: EXPERIMENTAL
Intervention: Supervised methadone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Flexible take-home dosing buprenorphine/naloxone
Number of subjects: 269
Study: 38721680

Group type: EXPERIMENTAL
Intervention: Oral preparation of hyaluronic acid, chondroitin sulfate, N-acetylglucosamine, and vitamin C once a day for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received an oral preparation of cranberry, D-mannose, propolis extract, turmeric, and Boswellia twice a day for 3 months
Number of subjects: 50
Study: 38721977

Group type: EXPERIMENTAL
Intervention: Automated vertebral fracture assessment using chest CT
Number of subjects: 3231

Group type: EXPERIMENTAL
Intervention: Automated vertebral segmentation module
Number of subjects: 3231

Group type: EXPERIMENTAL
Intervention: Automated vertebral labelling module
Number of subjects: 3231

Group type: EXPERIMENTAL
Intervention: Automated vertebral segmentation for low dose CT
Number of subjects: 3231

Group type: EXPERIMENTAL
Intervention: Fracture assessment from low dose CT
Number of subjects: 3231
Study: 38722221

Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance therapy
Number of subjects: 79
Study: 38722325

Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP concentrations in the Explorys cohort (median 1250 pg/mL)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Plasma NT-proBNP concentrations in the PCMR cohort (median 184 pg/mL)
Number of subjects: 259
Study: 38722346

Group type: EXPERIMENTAL
Intervention: Serious game with the REAplan
Number of subjects: 0
Study: 38722461

Group type: COMPARATOR
Intervention: Normal renal function (GFR ≥ 90 mL/min)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Normal hepatic function
Number of subjects: 83
Study: 38722537

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 50
Study: 38722621

Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib after cycle 20.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent imatinib after cycle 20.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ponatinib (30 mg/d)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Imatinib (600 mg/d)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 232

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 232
Study: 38722641

Group type: EXPERIMENTAL
Intervention: Nivolumab induction (240 mg every 2 weeks)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (3 mg/kg + 1 mg/kg, followed by 1 mg/kg + 3 mg/kg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (1 mg/kg + 3 mg/kg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab (high-dose)
Number of subjects: 169
Study: 38722644

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monthly (15 mg per 0.1-mL intravitreal injection)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan every other month (15 mg per 0.1-mL intravitreal injection)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan monthly vs pegcetacoplan every other month
Number of subjects: 936

Group type: COMPARATOR
Intervention: Sham injection (monthly or every other month)
Number of subjects: 936
Study: 38722664

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) at 0.6 mg/m2 on day 8 and day 15 of a 28-day cycle combined with DA-EPOCH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) combined with DA-EPOCH
Number of subjects: 24
Study: 38722831

Group type: EXPERIMENTAL
Intervention: Sit Less program (12-week intervention including goal-setting session, Fitbit, smart water bottle, weekly text messages)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sit Less program
Number of subjects: 70

Group type: COMPARATOR
Intervention: American Heart Association's 'Answers by Heart' fact sheets
Number of subjects: 70
Study: 38722838

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver (30 cmH2O for 30 s applied at three time points)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no alveolar recruitment maneuver)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 38722926

Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based intervention (weekly 90-minute group sessions for four consecutive weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Current standard of care (control group)
Number of subjects: 122
Study: 38723189

Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol with individualized fixed daily dose of follitropin delta
Number of subjects: 437

Group type: COMPARATOR
Intervention: GnRH antagonist protocol with individualized fixed daily dose of follitropin delta
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol
Number of subjects: 437

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 437
Study: 38723214

Group type: EXPERIMENTAL
Intervention: Culturally competent education and HPV self-sampling
Number of subjects: 40
Study: 38723227

Group type: EXPERIMENTAL
Intervention: Nivolumab + relatlimab + chemotherapy
Number of subjects: 274

Group type: COMPARATOR
Intervention: Nivolumab + chemotherapy
Number of subjects: 274
Study: 38723373

Group type: EXPERIMENTAL
Intervention: encorafenib 450 mg QD plus binimetinib 45 mg BID
Number of subjects: 577

Group type: COMPARATOR
Intervention: vemurafenib 960 mg BID
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: encorafenib monotherapy 300 mg QD
Number of subjects: 577
Study: 38723593

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Prostatectomy (RALP)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Open Radical Retropubic Prostatectomy
Number of subjects: 342
Study: 38723617

Group type: EXPERIMENTAL
Intervention: Investigational gene therapies for RTT
Number of subjects: 0
Study: 38723644

Group type: EXPERIMENTAL
Intervention: Maralixibat (starting dose 142.5 μg/kg, then escalated to 570 μg/kg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Maralixibat
Number of subjects: 93
Study: 38723650

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 1500
Study: 38723858

Group type: EXPERIMENTAL
Intervention: Modified ShortMAC-F
Number of subjects: 114
Study: 38723867

Group type: EXPERIMENTAL
Intervention: Robotic hepatectomy
Number of subjects: 3448

Group type: COMPARATOR
Intervention: Laparoscopic hepatectomy
Number of subjects: 3448

Group type: COMPARATOR
Intervention: Open hepatectomy
Number of subjects: 3448
Study: 38723880

Group type: EXPERIMENTAL
Intervention: AI-QCA-assisted PCI strategy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Optical coherence tomography-guided PCI strategy
Number of subjects: 400
Study: 38723981

Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 38724038

Group type: EXPERIMENTAL
Intervention: Composite sleep health score
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Irregularity (individual sleep dimension)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Poor satisfaction (individual sleep dimension)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Lower alertness (individual sleep dimension)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Composite sleep health scores and individual sleep dimensions
Number of subjects: 257
Study: 38724058

Group type: EXPERIMENTAL
Intervention: Intravenous injections of ICG twice with intraoperative assessment of anastomotic blood flow using the near-infrared NIR-ICG system during total mesorectal excision (TME) surgery.
Number of subjects: 712

Group type: COMPARATOR
Intervention: Conventional TME surgery without the use of the NIR-ICG system.
Number of subjects: 712
Study: 38724182

Group type: EXPERIMENTAL
Intervention: belimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 38724231

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) local field potentials (LFPs) recorded during NREM sleep
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) local field potentials (LFPs)
Number of subjects: 13
Study: 38724259

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 0
Study: 38724261

Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 38724266

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Total inhalational anaesthesia
Number of subjects: 50
Study: 38724293

Group type: EXPERIMENTAL
Intervention: felcisetrag 0.5 mg daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: felcisetrag 0.5 mg pre-surgery
Number of subjects: 209

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209
Study: 38724408

Group type: EXPERIMENTAL
Intervention: Ad hoc procedures
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Planned procedures
Number of subjects: 101

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 101
Study: 38724531

Group type: EXPERIMENTAL
Intervention: Longer (18-to-20 month) regimen for MDR/RR TB
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Cavitary disease
Number of subjects: 1286

Group type: COMPARATOR
Intervention: BMI < 18.5
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Hepatitis C
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Prior treatment with second-line drugs
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Longer time to initial culture conversion
Number of subjects: 1286
Study: 38724605

Group type: EXPERIMENTAL
Intervention: Bovine milk-derived human milk fortifier (HMF) with first feedings
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delayed fortification at 80 ml/kg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bovine milk-derived human milk fortifier (HMF)
Number of subjects: 52
Study: 38724826

Group type: EXPERIMENTAL
Intervention: Higher protein diet intervention (increased protein from ~10-15E% to ~25E%)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Lifestyle camp intervention (10 weeks duration)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Higher protein diet intervention
Number of subjects: 208
Study: 38724831

Group type: EXPERIMENTAL
Intervention: Holograms (HG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Computed Tomography (CT) images
Number of subjects: 52
Study: 38724841

Group type: EXPERIMENTAL
Intervention: Clindamycin 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% gel (CAB)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 363
Study: 38724874

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (AHT) targeting systolic blood pressure (SBP) ≤140 mmHg for a median duration of 7 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment (AHT)
Number of subjects: 14
Study: 38724879

Group type: EXPERIMENTAL
Intervention: Reassuring instructions
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control instructions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neutral instructions
Number of subjects: 72
Study: 38724889

Group type: EXPERIMENTAL
Intervention: Weibull parametric model
Number of subjects: 491

Group type: COMPARATOR
Intervention: Cox proportional hazards (CPH) model
Number of subjects: 491
Study: 38724947

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 38724961

Group type: EXPERIMENTAL
Intervention: ØCD prevention program (six online group sessions incorporating CBT and ERP techniques)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ØCD prevention program
Number of subjects: 0
Study: 38724991

Group type: EXPERIMENTAL
Intervention: Molecularly guided treatment (MGT) informed by molecular tumor boards (MTBs)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tier 1: Therapeutic use of investigational drugs targeting genetic alterations (e.g., ALK, EGFR, ERBB2, BRAF, FH, ROS1, RET)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tier 2: Drugs with approved indications or permitted for treatment outside of approved indications
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tier 3: Clinical trials matching the genetic alterations recommended by the MTB
Number of subjects: 1000
Study: 38725194

Group type: EXPERIMENTAL
Intervention: Intraovarian PRP injection
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 83
Study: 38725258

Group type: COMPARATOR
Intervention: Matching placebo D/C/F/TAF tablets
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo D/C/TAF tablets
Number of subjects: 24
Study: 38725287

Group type: EXPERIMENTAL
Intervention: Trans-subxiphoid robotic surgery using da Vinci SP platform for maximal thymectomy
Number of subjects: 15
Study: 38725307

Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38725398

Group type: EXPERIMENTAL
Intervention: Relief drinking group
Number of subjects: 169

Group type: COMPARATOR
Intervention: Reward drinking group
Number of subjects: 169
Study: 38725985

Group type: EXPERIMENTAL
Intervention: Melatonin (Mel)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 156
Study: 38725995

Group type: EXPERIMENTAL
Intervention: High-dose encorafenib 300 mg BID plus binimetinib 45 mg BID
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard-dose encorafenib 450 mg QD plus binimetinib 45 mg BID
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Escalated dose encorafenib 600 mg QD plus binimetinib 45 mg BID
Number of subjects: 13
Study: 38726027

Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 75
Study: 38726365

Group type: EXPERIMENTAL
Intervention: Batiraxcept in combination with durvalumab
Number of subjects: 11
Study: 38726646

Group type: EXPERIMENTAL
Intervention: Culturally tailored low-glycaemic index dietary educational intervention
Number of subjects: 166

Group type: COMPARATOR
Intervention: General advice on a healthy diet (control group)
Number of subjects: 166
Study: 38726850

Group type: EXPERIMENTAL
Intervention: Limited Driving Pressure (LDP; ⩽15 cmH2O)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Low Tidal Volume (LTV)
Number of subjects: 126
Study: 38726886

Group type: EXPERIMENTAL
Intervention: 1 avocado per day for 6 months
Number of subjects: 134

Group type: COMPARATOR
Intervention: Habitual diet low in avocados
Number of subjects: 134
Study: 38726892

Group type: COMPARATOR
Intervention: Shared decision-making (SDM) involving all components
Number of subjects: 64215

Group type: COMPARATOR
Intervention: Abbreviated forms of SDM with clarification of values and preferences
Number of subjects: 64215

Group type: COMPARATOR
Intervention: Enhanced communication about risks without other SDM aspects
Number of subjects: 64215
Study: 38726920

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) concentration
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Time to the composite of clinically relevant arrhythmia, hospitalization for heart failure, or all-cause death
Number of subjects: 98
Study: 38727191

Group type: EXPERIMENTAL
Intervention: Vesatolimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38727516

Group type: EXPERIMENTAL
Intervention: Decision Regret Scale (DRS) survey 3-5 weeks post-PICU discharge
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Parental Hispanic ethnicity
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Increased PICU length of stay (LOS)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Underlying respiratory disease
Number of subjects: 233
Study: 38727649

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 700

Group type: COMPARATOR
Intervention: OMT
Number of subjects: 700
Study: 38727726

Group type: EXPERIMENTAL
Intervention: Evicel
Number of subjects: 40
Study: 38727837

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg once every 3 weeks via intravenous infusion) plus famitinib (20 mg once daily)
Number of subjects: 40
Study: 38727860

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (PEG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Eculizumab (ECU)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Eculizumab to Pegcetacoplan (ECU-to-PEG)
Number of subjects: 41
Study: 38727945

Group type: EXPERIMENTAL
Intervention: Standard instrumentation and techniques for cup placement
Number of subjects: 170
Study: 38728033

Group type: EXPERIMENTAL
Intervention: Blood pressure self-monitoring plus medication self-titration
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study: 38728244

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 23
Study: 38728323

Group type: EXPERIMENTAL
Intervention: In-bed cycling/stepping in addition to conventional rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 0
Study: 38728337

Group type: EXPERIMENTAL
Intervention: Avelumab plus best supportive care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 0
Study: 38728364

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOXIRI (triplet arm)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Cetuximab plus FOLFOX (doublet arm)
Number of subjects: 146
Study: 38728564

Group type: EXPERIMENTAL
Intervention: Best practice hearing intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 150
Study: 38728603

Group type: EXPERIMENTAL
Intervention: Dual diagnosis group (patients with substance use disorder and personality disorders)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patients taking treatment for substance use disorder
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Females and alcohol abusers
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Patients with SUD and PDs
Number of subjects: 118
Study: 38728925

Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Heparin-mediated extracorporeal LDL-precipitation (HELP)-apheresis
Number of subjects: 8
Study: 38729196

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 (0.5 mL intramuscular injections of modified vaccinia Ankara expressing H3N2 nucleoprotein and matrix protein 1)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: MVA-NP+M1
Number of subjects: 145